Age: 78.0
Sex: F
Vaccine: COVID19, VARZOS
Symptoms: Pyrexia
Clinical narrative: Pyrexia; Chills; Muscle spasms; Dizziness; Headache; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of fever in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included dupilumab (Dupixent) solution for injection (batch number 2LU42Z, expiry date 31-MAY-2025) for atopic dermatitis and COVID 19 VACCINE for prophylaxis.   Concurrent medical conditions included asthma.   On an unknown date, the patient received Shingrix. In MAR-2023, the patient started Dupixent (subcutaneous) 300 mg 600 mg daily (600 mg daily). On an unknown date, the patient received COVID 19 VACCINE. On an unknown date, an unknown time after receiving Shingrix, the patient experienced fever (Verbatim: Pyrexia), chills (Verbatim: Chills), muscle spasm (Verbatim: Muscle spasms), dizziness (Verbatim: Dizziness) and headache (Verbatim: Headache). The action taken with Dupixent was unknown. The outcome of the fever, chills, muscle spasm, dizziness and headache were resolving.   It was unknown if the reporter considered the fever, chills, muscle spasm, dizziness and headache to be related to Shingrix.     It was unknown if the company considered the fever, chills, muscle spasm, dizziness and headache to be related to Shingrix.   Additional Information: GSK receipt date: 30-May-2023 Initial information received on 01 April 2023 regarding an unsolicited valid non-serious case received from United States via patient (non health care professional). This case was self reported by the patient. The patient's past medical history, medical treatments, concomitants and family history were not provided. The patient experienced fever, chills after the injection, muscle cramps, dizzy, headache and reported it is not helping much with her eczema yet with no adverse event while receiving vaccine Covid-19 vaccine and while treated with Dupilumab (dupixent) using prefilled syringe and varicella zoster vaccine rge (cho) Shingrix. At the time of the event, the patient had ongoing Asthma NOS. On an unknown date in March 2023, the patient started taking Dupixent (dupilumab) with strength 300mg 2ml Solution for injection as loading dose 600 mg 1time once followed by maintenance des 300 mg 00 (every other week) Information regarding lot batch and expiration date was quited. On an unknown date, the patient started taking Shingrix (varicella zoster vaccine rge (cho) unknown dosage unknown with an unknown batch number for Immunization. On an unknown date, the patient received a dose of suspect Covid-19 vaccine not produced by Sanofi Pasteur lot number not reported. On an unknown date in 2023 the patient developed a non-serious event reported it was not helping much with her eczema yet with no adverse event (therapeutic response decreased) few days latency, following the first dose intake of Dupilumab and Varicella zoster vaccine rge (cho) and following the administration of covid-19 vaccine. On an unknown date in 2023, the patient developed a non-serious event fever (pyrexia), chills after the injection (few days' latency following the first dose intake of dupilumab and varicella zoster vaccine rge (cho) and following the administration of covid-19 vaccine. On an unknown date, the patient developed a non-serious event muscle cramps, dizzy (dizziness), and headache with unknown latency following the first dose intake of Dupilumab and Varicella zoster vaccine rge (cho) and following the administration of covid-19 vaccine. On an unknown date, the relevant laboratory test results included body temperature on an unknown date (fever) and oxygen saturation that blood oxygen would normal run in the low 80s, now in the mid 90s The medication was helping with her asthma patient also reported it is not helping much with her eczema yet.  The patient had a covid vaccine and shingles vaccine and is now experiencing fever, chills, dizzy, headache, muscle cramps. Patient reports she is feeling better today. No action taken for pyrexia and chills, muscle spasms, dizziness and headache and not applicable for other event. Action taken with Covid-19 vaccine and Varicella zoster vaccine rge (cho) (Shingrix) was not applicable. It was not reported if the patient received a corrective treatment for the events (fever, chills after the injection, muscle spasms, headache and dizziness). The outcome for therapeutic response decreased was unknown and for all rest other events was recovering. Time to onset and causality was unknown if the reporter considered the events to be related to Dupixent, Covid 19.